Andrew Zupnick, PhD
Vice President, Oncology Drug Development
Andrew Zupnick, PhD, has more than 25 years of experience focused exclusively on oncology. As Vice President of Oncology Drug Development for Worldwide, he supports study optimization, delivery oversight, training, and the development of new initiatives across commercial and operational teams to ensure Worldwide remains at the forefront of industry trends and emerging oncology therapies.
Ask Dr. Zupnick a question
Submit an RFP. Ask a Question
A cell and molecular biologist by training, Andrew holds a PhD, MS, and MA from Columbia University, as well as a BS from MIT. He brings a broad and integrated oncology perspective to Worldwide, informed by nearly two decades of experience across commercial and operational leadership roles within specialty oncology CROs.
Andrew began his professional career at Prologue Research, a niche oncology CRO founded from what became The James Cancer Center at The Ohio State University. Prologue was acquired by Novella Clinical in 2010. Following Novella’s acquisition by Quintiles, Andrew spent nearly seven years leading the global oncology strategy team within the standalone CRO business, later rebranded as IQVIA Biotech in 2019. In this role, he helped shape and execute global oncology development strategies for biopharmaceutical companies across a wide range of tumor types and development stages.
